PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Jeonjin Biopharm, a natural-material-based pest/damage-reduction and household-goods maker, swung back to operating and net losses in 2025 after a profitable 2024, with losses continuing through the first half of 2026, though its debt ratio remains in the single digits and its balance sheet stays stable.
2025 revenue fell to KRW 13.69 billion from KRW 19.27 billion in 2024, with both operating profit and net income turning negative
Q3 2025 operating profit peaked at KRW 0.33 billion among recent quarters, but the company slipped back into losses from Q4 2025
Operating losses continued in both Q1 and Q2 2026, with revenue still trending below the prior year
The debt ratio stood at 6.3% at end-2025, reflecting a very low-leverage balance sheet
Slowing demand for its core capsule laundry detergent product and intensifying retail-channel competition are the key drivers of earnings volatility
Founded in 2004 and listed on KOSDAQ, Jeonjin Biopharm's core business is 'damage-reduction agents' that prevent and reduce harm from pests and nuisance wildlife, built on a natural-material library.
Its flagship product lines include bird damage-reduction agents, insect repellents (Pari Segem brand), and wildlife-response products (BreedCan brand), and the company has leveraged this technology to expand into household goods.
In the household segment, it manufactures and sells capsule-type laundry detergent, liquid detergent and fabric softener, dishwasher detergent capsules, and air fresheners/deodorizers under the Wash & Wish brand. It has further diversified into pet/animal-care products to broaden its portfolio.
Its product differentiation strategy emphasizes natural-material-based 5-in-1 technology, vegan (V-label) certification, and German Dermatest certification. Distribution is heavily reliant on large retail channels, which has historically made earnings sensitive to shifts in channel bargaining power and sales terms.
More recently, the company has pursued expansion of small-package product distribution and diversification of export channels to broaden its sales base.
Competitively, the household goods market is a near-red-ocean environment against large consumer-goods rivals, while the damage-reduction agent segment is regarded as a relatively niche market with entry barriers.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩3.6B | ₩86,210,130 | 2.4% |
| 2025Q3 | ₩4.5B | ₩300M | 7.3% |
| 2025Q4 | ₩3.4B | -₩300M | −8.1% |
| 2026Q1 | ₩2.9B | -₩200M | −6.9% |
| 2026Q2 | ₩2.9B | -₩300M | −8.9% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩7.8B | -₩3.2B | -₩3.2B | −40.8% | −33.2% | 87.9% |
| 2023 | ₩15.7B | -₩1.2B | -₩6.4B | −7.9% | −103.5% | 184.6% |
| 2024 | ₩19.3B | ₩1.2B | ₩4.3B | 6.0% | 24.6% | 6.7% |
| 2025 | ₩13.7B | -₩300M | -₩200M | −2.5% | −1.1% | 6.3% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Jeonjin Biopharm's earnings have shown significant volatility over the past four fiscal years.
After a large loss in 2022 with revenue of KRW 7.79 billion and an operating loss of KRW 3.18 billion (operating margin -40.8%), 2023 revenue grew to KRW 15.68 billion, yet the operating loss widened to KRW 1.24 billion and the net loss reached KRW 6.44 billion, while the debt ratio surged to 184.6%.
In 2024, the company achieved a turnaround with revenue of KRW 19.27 billion, operating profit of KRW 1.16 billion (operating margin 6.0%), and net income of KRW 4.35 billion, with the debt ratio improving sharply to 6.7%.
However, in 2025 revenue fell back to KRW 13.69 billion, and the company posted an operating loss of KRW 0.34 billion (operating margin -2.5%) and a net loss of KRW 0.20 billion, reverting to losses.
On a quarterly basis, Q3 2025 was the strongest recent quarter, with revenue of KRW 4.45 billion and operating profit of KRW 0.33 billion, but the trend reversed in Q4 2025 as revenue fell to KRW 3.44 billion alongside an operating loss of KRW 0.28 billion.
Losses continued into Q1 2026 (revenue KRW 2.88 billion, operating loss KRW 0.20 billion) and Q2 2026 (revenue KRW 2.94 billion, operating loss KRW 0.26 billion), with no improvement in profitability throughout the first half.
Over the trailing four quarters (Q3 2025 through Q2 2026), net income attributable to owners totaled a loss of KRW 0.31 billion, indicating that the 2024 profit recovery has not been sustained.
This pattern reflects a business structure where seasonal demand swings in core household products and shifts in retail-channel bargaining power feed directly into profitability.
The household goods market in which Jeonjin Biopharm operates is a mature industry with numerous large consumer-goods competitors; core products such as capsule laundry detergent face intense price competition and low entry barriers due to heavy reliance on large domestic and overseas retail channels.
FnGuide attributed the 2025 decline in standalone revenue to weaker demand for its flagship capsule laundry detergent, intensified competition in the household goods market, and profitability erosion tied to its dependence on large retail channels.
Demand for the flagship capsule laundry detergent declined and competition in the household goods market intensified, reducing revenue, while profitability worsened due to dependence on large retail channels.
By contrast, the damage-reduction agent (pest/wildlife control) segment is a comparatively niche market requiring natural-material technology, and the shift from chemical control toward eco-friendly materials is spreading, mainly in developed markets, suggesting potential for continued substitute demand over the medium to long term.
That said, this segment does not yet appear to have grown to represent an absolute majority of overall company revenue.
Relative to competitors, the company is at a disadvantage in household goods against scale-advantaged large players, while in damage-reduction agents it is attempting technological differentiation via its proprietary natural-material library and certifications (vegan V-label, German Dermatest).
There is limited evidence to date that the industry has entered a clear growth phase, and the company's revenue scale remains at the level of a small KOSDAQ-listed firm fluctuating in the range of roughly KRW 10-19 billion annually.
The company is pursuing product differentiation in its household goods segment—centered on natural-material-based 5-in-1 technology, vegan (V-label) certification, and German Dermatest certification—as a way to reduce dependence on large retail channels.
The company is building product differentiation through natural-material-based 5-in-1 technology, vegan V-label certification, and German Dermatest certification, while pursuing expanded distribution of small-package products and diversification of export channels.
In the damage-reduction agent segment, the company has continued expanding its product lineup against nuisance wildlife and pests using its natural-material library, and past disclosures have referenced longer-term expansion into new applications such as sea lice (fish parasite) control.
That said, recent disclosures mainly point to a pattern of declining revenue and a swing back into losses, and no specific numerical guidance from management has been identified.
Given the losses that persisted through the first half of 2026, whether the seasonal strength seen in Q3 2025 recurs in the second half, or whether retail-channel competition continues to intensify, appears to be a key swing factor for future results.
On the balance-sheet side, the company's low debt ratio suggests relatively limited pressure for external financing at this stage.
Because the company continues to post net losses, earnings-based valuation metrics carry limited meaning at this stage. The share price trades at a level close to per-share net asset value, without a pronounced premium or discount to net assets.
Considering the earnings cycle—from the large 2023 loss and elevated debt ratio, to the 2024 turnaround to profit, and back to a 2025 loss—market valuation appears to reflect that confidence in earnings stability has not yet firmly taken hold.
No dividend payment has been identified based on the most recent confirmed financials. On the balance-sheet side, the debt ratio remains in the single digits, meaning earnings volatility—rather than financial risk—is the more important variable in any valuation discussion.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
The debt ratio at end-2025 stood at 6.3%, sharply down from 184.6% in 2023. This reflects the lingering effect of balance-sheet improvement during the 2024 profit turnaround, keeping pressure for external financing relatively low. Despite earnings volatility, the risk of capital impairment or a liquidity crisis currently appears limited.
The company holds differentiating elements built on its natural-material library, including 5-in-1 technology, vegan V-label certification, and German Dermatest certification.
Its damage-reduction agent segment aligns with the trend favoring eco-friendly materials over chemical control, leaving room to sustain technical competitiveness in a niche market. Such certifications and technology may help partly avoid direct price competition with larger rivals.
The company has a track record of turning around from large losses in 2022-2023 to a 2024 profit, with revenue of KRW 19.27 billion, an operating margin of 6.0%, and net income of KRW 4.35 billion. This shows the business can see rapid profitability improvement when revenue recovery and cost control align. Q3 2025 also showed improved quarterly operating profit.
2025 revenue fell to KRW 13.69 billion from the prior year, and both operating profit and net income turned negative. Losses continued in both Q1 and Q2 2026, with no clear sign of profitability improvement.
Trailing four-quarter net income also remains in loss territory, raising the possibility that the 2024 profit recovery was temporary.
The company's core household product, capsule laundry detergent, is heavily dependent on large retail channels, making results vulnerable to shifts in channel bargaining power. FnGuide pointed to intensifying competition in the household goods market as a key factor behind profitability erosion. This suggests the company's own brand strength alone may not be sufficient to defend pricing and volume terms.
Given the company's small scale, with annual revenue fluctuating between roughly KRW 10-19 billion, swings in individual quarters or client relationships have an outsized effect on overall profit and loss. The reversal from a strong Q3 2025 straight into a Q4 2025 loss illustrates this well. Such volatility adds uncertainty to future earnings estimates.
The household goods segment is heavily dependent on large retail channels, so results are directly affected by changes in channel sales terms or promotional policies. The damage-reduction agent segment remains relatively small in revenue scale and has not yet grown enough to offset overall results.
Because segment revenue breakdown is not clearly disclosed, it is difficult to objectively gauge the diversification benefit across the two businesses.
Disclosure history indicates the company has experienced governance-related disputes, including litigation and the cancellation/dismissal of a request to convene an extraordinary shareholders' meeting.
While a regular shareholders' meeting was held in March 2026, the past dispute history remains a source of uncertainty regarding governance stability. Whether similar disputes recur going forward warrants monitoring.
Of the four years from 2022 to 2025, only 2024 was profitable, while the other three years all recorded operating losses. This earnings discontinuity provides grounds to view any future return to profit with caution regarding its sustainability.
Combined with the low revenue base typical of a small KOSDAQ company, uncertainty in earnings forecasting is a persistent feature.
The Q3 2026 quarterly report is due — check whether seasonal strength similar to Q3 2025 (operating profit of KRW 0.33 billion) recurs, and whether the loss trend from the first half improves.
Monitor IR communications or disclosures on small-package distribution expansion and export channel diversification, which could provide evidence of real progress in reducing dependence on large retail channels.
The 2026 annual business report is due — a key indicator to determine whether the 2025 return to loss was a one-off event or a structural trend, and whether the company returns to annual profitability.
Check the notice for the next regular shareholders' meeting — given the past history of disputes over extraordinary shareholders' meeting requests, it is worth monitoring whether governance-related issues resurface.
Jeonjin Biopharm is a small KOSDAQ-listed biopharma company with a two-pillar business structure spanning natural-material-based damage-reduction agents and household goods, and its results over the past four years have shown pronounced swings.
After a large loss and a high debt ratio crisis in 2023, the company achieved a profit turnaround in 2024, but reverted to operating and net losses in 2025 alongside declining revenue, a trend that has continued through the first half of 2026.
Even so, the debt ratio remains in the single digits, meaning the balance sheet has stayed relatively stable despite earnings volatility.
On the business side, the company shows differentiation through natural-material technology and certifications, along with a strategy to expand export and small-package channels, but structural constraints such as dependence on large retail channels and intensifying market competition persist.
A past history of governance-related disputes is also a factor investors should weigh. Upcoming Q3 results and the annual business report should help clarify whether the 2025 return to loss was a temporary event or a structural trend. This report is prepared for informational purposes and does not include a buy or sell recommendation.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.